Characteristics | Whole Population | BMI, n = 207* | p | ||
---|---|---|---|---|---|
< 25 kg/m2 | 25–30 kg/m2 | > 30 kg/m2 | |||
Patients, n (%) | 222 | 121 (58.5) | 54 (26.0) | 32 (15.5) | |
Age, yrs | 56 (47–66) | 55 (46–65) | 58.5 (52–67) | 56 (48–63.5) | 0.29 |
Female sex | 82.4 | 83.5 | 77.8 | 93.7 | 0.15 |
Disease duration, yrs | 14 (8–22) | 15 (8–23.5) | 13 (8–24) | 11 (8.5–19) | 0.44 |
Erosive status | 79.0 | 83.5 | 75.0 | 62.5 | 0.03 |
RF-positive | 71.0 | 66.1 | 77.4 | 77.4 | 0.22 |
ACPA-positive | 65.7 | 67.2 | 63.5 | 64.5 | 0.88 |
Previous biologics use, median (min–max) | 2 (0–6) | 3 (0–6) | 2 (0–6) | 2 (0–6) | 0.08 |
Biologic-naive patients | 13.1 | 11.6 | 18.5 | 9.4 | 0.38 |
Concomitant therapy | |||||
MTX, n (%) | 105 (47.3) | 58 (47.9) | 25 (46.3) | 14 (43.7) | 0.91 |
MTX dose, mg/wk | 15 (10–15) | 15 (10–15) | 15 (10–15) | 15 (12.5–17.5) | 0.81 |
Steroid, n (%) | 143 (64.7) | 79 (65.8) | 35 (64.8) | 21 (65.6) | 0.99 |
Steroid dose, mg/day | 10 (5–10) | 10 (5–15) | 10 (5–10) | 8 (5–10) | 0.65 |
TCZ dose, mg/kg, median (min–max) | 8 (4–8) | 8 (4–8) | 8 (8–8) | 8 (8–8) | 0.24 |
Disease activity measures | |||||
TJC | 8 (5–13.5) | 7 (4–13) | 10 (5–16) | 8 (5.5–13) | 0.31 |
SJC | 4 (1–7) | 4 (1–7) | 4 (2–7) | 3 (1–5) | 0.25 |
ESR, mm/h | 27 (11–44) | 24 (10–39) | 28 (11–44) | 32 (21–57) | 0.07 |
CRP, mg/l | 8.0 (3–24.5) | 6.3 (2.6–24.8) | 8.0 (2.5–22.1) | 11.2 (7.4–24.1) | 0.11 |
DAS28-ESR, mean (SD) | 5.09 (1.28) | 5.04 (1.34) | 5.14 (1.36) | 5.22 (1.11) | 0.75 |
↵* 15 patients had missing values for weight and/or height. RA: rheumatoid arthritis; TCZ: tocilizumab; BMI: body mass index; IQR: interquartile range; RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; MTX: methotrexate; TJC: tender joint count; SJC: swollen joint count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints.